| P50 | author | Stephan von Haehling | Q50639680 |
| | Stefan D. Anker | Q30310195 |
| P2093 | author name string | Nicole Ebner | |
| P2860 | cites work | An overview of sarcopenia: facts and numbers on prevalence and clinical impact | Q24633887 |
| | Cardiac cachexia: hic et nunc | Q26744140 |
| | Dysfunction of respiratory muscles in critically ill patients on the intensive care unit | Q26749263 |
| | Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment | Q26775254 |
| | Pathophysiology of anorexia in the cancer cachexia syndrome | Q26775294 |
| | Biomarkers for physical frailty and sarcopenia: state of the science and future developments | Q26775328 |
| | Exercise for cancer cachexia in adults: Executive summary of a Cochrane Collaboration systematic review | Q26781637 |
| | Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training | Q26781640 |
| | Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved. | Q30384810 |
| | Wasting in chronic kidney disease | Q30432774 |
| | Assessing skeletal muscle mass: historical overview and state of the art | Q30441307 |
| | Are we closer to having drugs to treat muscle wasting disease? | Q33741103 |
| | Biomarkers of muscle quality: N-terminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults | Q33741109 |
| | The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. | Q34029187 |
| | Muscle wasting: an overview of recent developments in basic research | Q34156942 |
| | Anabolic exercise in haemodialysis patients: a randomised controlled pilot study | Q34156946 |
| | Assessing sarcopenic prevalence and risk factors in residential aged care: methodology and feasibility | Q34156968 |
| | Osteosarcopenic obesity: the role of bone, muscle, and fat on health | Q34156977 |
| | Cachexia as a major underestimated and unmet medical need: facts and numbers | Q34176827 |
| | Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones | Q34590954 |
| | Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile | Q34590963 |
| | Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure | Q34590981 |
| | Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. | Q34591002 |
| | Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. | Q34591010 |
| | Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. | Q34697114 |
| | The role of myostatin in muscle wasting: an overview | Q35223987 |
| | Improved body weight and performance status and reduced serum PGE2 levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastro-esophageal junction. | Q35617680 |
| | Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients | Q35617684 |
| | Understanding and managing cancer-related weight loss and anorexia: insights from a systematic review of qualitative research | Q35617700 |
| | Searching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS study | Q35690200 |
| | Impact of creatine supplementation in combination with resistance training on lean mass in the elderly. | Q36033744 |
| | One-year intranasal application of growth hormone releasing peptide-2 improves body weight and hypoglycemia in a severely emaciated anorexia nervosa patient | Q36074176 |
| | Behavioural changes are a major contributing factor in the reduction of sarcopenia in caloric-restricted ageing mice | Q36074187 |
| | Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia | Q36179100 |
| | Molecular and cellular mechanisms of skeletal muscle atrophy: an update. | Q36179105 |
| | Request for regulatory guidance for cancer cachexia intervention trials. | Q36349332 |
| | Rapid screening for sarcopenia | Q36349343 |
| | Skeletal muscle mass is associated with severe dysphagia in cancer patients. | Q36349367 |
| | Activin-βC modulates cachexia by repressing the ubiquitin-proteasome and autophagic degradation pathways. | Q36349376 |
| | From muscle wasting to sarcopenia and myopenia: update 2012 | Q36421054 |
| | SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes | Q36706584 |
| | Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients | Q36706626 |
| | Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone | Q36804101 |
| | Doxorubicin caused severe hyperglycaemia and insulin resistance, mediated by inhibition in AMPk signalling in skeletal muscle. | Q36892008 |
| | Muscle RING-finger 2 and 3 maintain striated-muscle structure and function | Q36892025 |
| | Increased expression of H19/miR-675 is associated with a low fat-free mass index in patients with COPD. | Q36892335 |
| | Patient-centred physical therapy is (cost-) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6 months follow-up | Q36892790 |
| | Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis | Q36892959 |
| | White adipose tissue cells and the progression of cachexia: inflammatory pathways. | Q36893021 |
| | Prevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of the COMO VAI? study | Q36893061 |
| | UBE2B is implicated in myofibrillar protein loss in catabolic C2C12 myotubes | Q36893085 |
| | Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting | Q36893329 |
| | Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study | Q36893336 |
| | From sarcopenia to frailty: a road less traveled | Q37635894 |
| | Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies | Q37635897 |
| | Sarcopenia: describing rather than defining a condition | Q38237001 |
| | Muscle wasting disease: a proposal for a new disease classification | Q38268470 |
| | Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015. | Q38670653 |
| | Conversion of leucine to β-hydroxy-β-methylbutyrate by α-keto isocaproate dioxygenase is required for a potent stimulation of protein synthesis in L6 rat myotubes | Q39218419 |
| | Megestrol acetate improves cardiac function in a model of cancer cachexia-induced cardiomyopathy by autophagic modulation | Q39726480 |
| | Influence of cancer cachexia on drug liver metabolism and renal elimination in rats | Q40771392 |
| | Hypermetabolism and symptom burden in advanced cancer patients evaluated in a cachexia clinic | Q40771523 |
| | p62/SQSTM1 but not LC3 is accumulated in sarcopenic muscle of mice | Q41426729 |
| | Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014 | Q41787049 |
| | Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? | Q41829893 |
| | Formoterol in the treatment of experimental cancer cachexia: effects on heart function | Q42062172 |
| | ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action beta-blocker | Q42398016 |
| | Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate | Q42456049 |
| | A framework for prescription in exercise-oncology research | Q42652182 |
| | Cachexia: a problem of energetic inefficiency. | Q43044556 |
| P433 | issue | 5 | |
| P921 | main subject | sarcopenia | Q1787939 |
| P304 | page(s) | 675-680 | |
| P577 | publication date | 2017-10-01 | |
| P1433 | published in | Journal of Cachexia, Sarcopenia and Muscle | Q6294897 |
| P1476 | title | Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017. | |
| P478 | volume | 8 | |